

Health System Performance Assessment: how well do European countries perform ?

Reinhard Busse, Prof. Dr. med. MPH FFPH

FG Management im Gesundheitswesen, Technische Universität Berlin
(WHO Collaborating Centre for Health Systems Research and Management)

&

European Observatory on Health Systems and Policies

Conflict of interest: nothing to disclose.

Funding from the German Federal Ministry of Research and education for the Berlin Centre of Health Economics Research (BerlinHECOR) „Towards a Performance Assessment of the German Health Care System“ and from the German Federal Ministry of Health for piloting a health system performance assessment is gratefully acknowledged.

What is Health System Performance Assessment (HSPA)?

„a country-specific process
of monitoring, evaluating, communicating and
reviewing
the achievement of high-level health system goals
based on health system strategies“



(WHO Regional Office for Europe, 2013)

Why do we need HSPA?


Health policy-making and reform require, first and foremost, a sound understanding of how a health system is performing.

Assessing the performance of a health system effectively is the first step to improving it.

(1) “Performance” needs (a) an understanding about systems’ objectives and (b) which elements (e.g. “functions”) contribute to achieving them




As linking goal outcomes to functions (or building blocks) directly is difficult, intermediate outcomes were added, where results can be better attributed (and influenced)



(2) “Performance” needs an agreement about which activities are part of the “health system” (and which are not)

“The **health care system**, not including public health activities or other wider issues”

(Hurst & Hughes 2001)




Pros and Cons of different health system boundaries in HSPA

- + Closer to concept of UHC
- + Accountability
- + Clarity in areas of action

- + More holistic view
- + Accounts for interactions




Health system boundaries




- Exclusion of (most) determinants
- Hard to measure effect on outcomes
- Slow change
- Lack of clarity on roles
- Hard to assign responsibility

In balance, I suggest that we need (A) HSPA, (B) health status reporting (burden of disease) and (C) Health Impact Assessment of non-medical determinants – separate but thought together ...




While again others argue that easy-to-understand relationships (between functions and key performance dimensions) are key for political acceptance of benchmarking activities




→ Both population health outcomes and responsiveness are the multiplicative effect of access and quality: *High accessibility but bad quality* as well as *low accessibility but high quality* lead, on the population level, to inferior outcomes (but pointing to the problem is important for deciding on reform need) 10

In reality, the framework needs to be a bit more complicated, taking (1) the burden of disease (or rather, the part which we define as “need”), (2) need categories & (3) equity considerations into account




... and adding “efficiency” again – HSPA is mainly looking at “system efficiency” but technical efficiency is also important




The access(ibility) dimension

(denominator: population/ persons with need)

Need (burden of disease amenable to health care)




x Quality = Outcomes (population health & responsiveness)



coverage (financial issues)


The three dimensions of decisions about the financing of services



Source: Expanded from Busse, Schreyögg and Gericke 2007

coverage (financial issues)

1st dimension/ population coverage:
the importance is known usually by U.S. data;
here: access problems due to costs




Notes: "Underinsured" refers to adults who were insured all year but experienced one of the following: out-of-pocket costs, excluding premiums, equaled 10% or more of income; out-of-pocket costs, excluding premiums, equaled 5% or more of income if low-income (<200% of poverty); or deductibles equaled 5% or more of income. "Uninsured anytime in the past year" refers to adults who were either uninsured at the time of the survey or spent some time uninsured in the past year.

Data: Commonwealth Fund Biennial Health Insurance Survey (2020).




2nd dimension/ covered benefits also matter:
e.g. gaps in dental care



Percent of adults age 65+ who reported they did not visit the dentist in the past year because of the cost, by country, 2020


Data: Commonwealth Fund 2021 International Health Policy Survey of Older Adults.



coverage (financial
issues)

3rd dimension/ cost-sharing: size and
protection mechanisms are important


***Experienced cost-related access
problem,***
i.e. had a medical problem but did not
visit doctor;
skipped medical test or treatment
recommended by doctor; or
did not fill prescription or skipped
doses because of cost.



Source: modified from 2016 Commonwealth Fund International Health Policy Survey in Eleven Countries.

coverage (financial issues)

Besides access problems, coverage gaps can lead to households facing catastrophic spending (and risk of impoverishment)




Note: Catastrophic spending on health calculated as more than 40% of HH expenditures on health care after expenditures on basic needs (housing, food, electricity, gas, heating).

Source: WHO Barcelona Office for Health Financing, 2023 forthcoming

availability of care

Urban-rural discrepancies are vary drastically between countries – with definite scope to learn from another

Figure 8.8. Physician density, urban vs. rural areas, 2019 (or nearest year)




1. In Korea, data for predominantly rural refer to intermediate regions (the share of the population living in rural areas is between 15-50%).

Source: OECD Regional Statistics Database 2021.


StatLink  <https://stat.link/qt6e5w>

waiting, acceptability etc.

Waiting (here: >4 weeks for a specialist appointment) is a general problem, but some countries see improvements and others not



(Self-reported) unmet need in selected countries (due to costs, distance, waiting), 2008-2021




eigene Darstellung auf Basis der EU-SILC (Statistisches Amt der Europäischen Union (Eurostat) 2021e).

Unmet
need

Unmet
need

Unmet need in selected EU countries by income quintiles (for costs, distance, waiting), 2016



Unmet
need

Unmet
need


Source: Eurostat Statistics Database

Note: Self-reported unmet needs due to financial reasons, distance or transportation, waiting list.


The quality dimension

(denominator: patients/ persons receiving services)


*Health-service only
performance dimension*




A major patient-relevant indicator of ambulatory care effectiveness: not being hospitalised in case of chronic conditions (“avoidable hospital admissions”) – here: here: chronic heart failure (left) and hypertension (right), *as main diagnosis*




- Germany
- Belgium
- Denmark
- France
- Netherlands
- Austria
- Sweden
- Switzerland
- UK
- Average (excl. DE)



Assessing the effectiveness of inpatient care: AMI case-fatality ... during hospitalisation only




... and looking at the first 30 days after AMI



Extending the time horizon to 5 years for cancer patients

6.34. Breast cancer five-year net survival, 2000-2004 and 2010-2014



Note: 95% confidence intervals have been calculated for all countries, represented by grey areas. Expected updates in the data may reduce the survival estimate for Costa Rica.

1. Data with 100% coverage of the national population.

Source: CONCORD programme, London School of Hygiene and Tropical Medicine.

10.9% die
within 5 years

26.5% die
within 5 years

A short look at
patient
experience
(responsiveness)
in ambulatory
care

Figure 6.8. Doctor involving patient in decisions about care and treatment, 2010 and 2020 (or nearest year)





Figure 6.7. Doctor providing easy-to-understand explanations, 2010 and 2020 (or nearest year)




Note: H lines show 95% confidence intervals. 1. Data from national sources. 2. Refers to patient experiences with regular doctor or regular practice.


Source: Commonwealth Fund International Health Policy Survey 2010 and 2020 and other national sources.

The population/system-wide outcomes

The areas with the least agreement but highest political relevance



How can we calculate the health system contribution to health?



The concept of avoidable mortality

- Deaths from certain causes that should not occur in the presence of timely and effective health care
- Introduced by David Rutstein in the 1970s (originally for quality assurance purposes)
- Walter Holland published European Community Atlas of 'Avoidable Deaths' in 1988; intends to provide warning signals of potential shortcomings in health care delivery
- Mackenbach et al. argue that associations between avoidable mortality and health care services are rather weak and inconsistent. Most health care measures only reflect quantity and not quality. Many studies use insufficient set of covariates.
- Nolte and McKee (2002) reviewed list of amenable causes of death

Dividing avoidable into “preventable” +
“treatable/ amenable” mortality (45 causes)


Short distinction (joint Eurostat/OECD approach since 2019):

Treatable (amenable) mortality: in the light of medical knowledge and technology at the time of death, all or most deaths from that cause (subject to age limits if appropriate) could be avoided through good quality healthcare.

+ Preventable mortality: in the light of understanding the determinants of health at the time of death, all or most deaths from that cause (subject to age limits if appropriate) could be avoided by public health interventions in the broadest sense.


= Avoidable mortality: all deaths defined as preventable, treatable (amenable), or both, where each death is counted only once.

Preventable causes of mortality



3x

Treatable causes of mortality




4x

■ Lung cancer
 ■ Alcohol related diseases
 ■ Ischaemic heart disease
 ■ Chronic lower respiratory diseases
 ■ Accidents (road and others)
 ■ Others

■ Ischaemic heart disease
 ■ Colorectal cancer
 ■ Breast cancer
 ■ Cerebrovascular disease
 ■ Pneumonia
 ■ Others


Applying the concept of treatable mortality longitudinally (2011-2020)

- Germany
- Belgium
- Denmark
- France
- Netherlands
- Austria
- Sweden
- Switzerland
- UK
- Average (excl. DE)




Applying the concept of treatable mortality longitudinally (2011-2020) and adding expenditure to get “system efficiency”

- Germany
- Belgium
- Denmark
- France
- Netherlands
- Austria
- Sweden
- Switzerland
- UK
- Average (excl. DE)



Efficiency – of high political relevance but few accepted indicators: here an example from the German HSPA



Similar starting point,
but very different development:
need to look into structural differences/
reforms during that time

Take-home messages:

1. There is a good agreement of what a good (high-performing) health system should achieve: accessibility, quality, population-wide outcomes and efficiency (value-for-money).
2. For many dimensions, there is also agreement on indicators, and data to fill them. But especially patient-reported data are not available in a coherent manner ... and for some dimensions (e.g. efficiency) conceptual issues are still debated.
3. However, for any kind of data to be used for improving performance requires (a) that we realize we may not be the best, (b) look at international data, (c) acknowledge scope for improvement, and (d) are willing to learn from others.